Actividad económica, consumo final de energía y requerimientos de energía primaria en Cataluña, 1990-2005. Análisis mediante el uso de los balances energéticos desde una perspectiva input-output

Este trabajo analiza la evolución de los consumos finales de energía en Cataluña durante el periodo 1990-2005. En conjunto, los consumos finales de energía crecen por encima del crecimiento del PIB en términos reales. La disponibilidad actual de datos permite una desagregación en cinco actividades: sector primario; sector industrial; sector servicios; transporte; y sector doméstico. Los aumentos relativos más importantes se dan en los sectores servicios, doméstico y transporte. Es esta última actividad (que incluye el transporte privado y comercial) la que experimenta un mayor aumento en términos absolutos, hasta llegar a representar un consumo final de energía.

Actividad económica y emisiones de CO2 derivadas del consumo de energía en Cataluña, 1990-2005. Análisis mediante el uso de los balances energéticos desde una perspectiva input-output

A lo largo del trabajo hemos analizado, tanto desde una perspectiva agregada, como posteriormente con todo el detalle posible, la evolución experimentada por estas emisiones, teniendo en cuenta las limitaciones de información . Para hacerlo se han utilizado conceptos y precisiones metodológicas ampliamente utilizadas en la literatura científica sobre el tema. Del estudio realizado en la primera parte del trabajo resulta evidente que el importante crecimiento de las emisiones en Cataluña durante el periodo considerado, de un 60.1%, muy superior a la media española (50,5%), se explica como principal factor por el aumento en el PIB per cápita, con un crecimiento del 33,35% . El crecimiento demográfico también habría contribuido de forma importante al incremento en las emisiones totales, con un aumento del 10,5% de la población; sobre todo a partir de 1999, ya que en la década de los noventa la población se mantuvo estable con pocas.

La Adaptación de la asignatura historia económica mundial en el Espacio Europeo de Educación Superior: objetivos y primeros resultados en la Facultad de Ciencias Económicas y Empresariales de la UAB

El crédito ECTS (European Credit Transfert System) no es solamente un instrumento de transferencia que facilita el reconocimiento de los títulos en toda la UE y la movilidad de estudiantes y profesores, sino un nuevo marco normativo donde los estudios de grado y postgrado se desarrollan a lo largo de un proceso acumulativo de aprendizaje. El objetivo de la reforma, una vez sentadas las bases del adiestramiento personal, es que el mencionado aprendizaje pueda continuar actuando a lo largo de toda la vida (Long Life Learning – LLL). La asignatura de Historia Económica Mundial (HEM) puede constituir una plataforma privilegiada sobre la cual aplicar los planes pilotos de transición hacia la implantación definitiva del EEES. La existencia de esta materia de estudio en los programas de las actuales titulaciones de Economía y Administración y Dirección de Empresas, destinadas a convertirse en el grado de Economía, se hace más necesaria que nunca, dado que reúne una serie de características intrínsecas que favorecen las prácticas de autoaprendizaje.

Long-term follow-up of high-dose chemotherapy with autologous stem-cell transplantation and response-adapted whole-brain radiotherapy for newly diagnosed primary CNS lymphoma: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkologie OSHO-53 phase II study

Introduction: We previously reported the results of a phase II study for patients with newly diagnosed primary CNS lymphoma (PCNSL) treated with autologous peripheral blood stem-cell transplantation (aPBSCT) and responseadapted whole brain radiotherapy (WBRT). The purpose of this report is to update the initial results and provide long-term data regarding overall survival, prognostic factors, and the risk of treatment-related neurotoxicity.Methods: A long-term follow-up was conducted on surviving primary central nervous system lymphoma patients having been treated according to the ,,OSHO-53 study", which was initiated by the Ostdeutsche Studiengruppe Hamatologie-Onkologie. Between August 1999 and October 2004 twentythree patients with an average age of 55 and median Karnofsky performance score of 70% were enrolled and received high-dose mthotrexate (HD-MTX) on days 1 and 10. In case of at least a partial remission (PR), high-dose busulfan/ thiotepa (HD-BuTT) followed by aPBSCT was performed. Patients without response to induction or without complete remission (CR) after HD-BuTT received WBRT. All patients (n=8), who are alive in 2011, were contacted and Mini Mental State examination (MMSE) and the EORTC QLQ-C30 were performed.Results: Eight patients are still alive with a median follow-up of 116,9 months (79 - 141, range). One of them suffered from a late relapse eight and a half years after initial diagnosis of PCNSL, another one suffers from a gall bladder carcinoma. Both patients are alive, the one with the relapse of PCNSL has finished rescue therapy and is further observed, the one with gall baldder carcinoma is still under therapy. MMSE and QlQ-C30 showed impressive results in the patients, who were not irradiated. Only one of the irradiated patients is still alive with a clear neurologic deficit but acceptable quality of life.Conclusions: Long-term follow-up of our patients, who were included in the OSHO-53 study show an overall survival of 30 percent. If WBRT can be avoided no long-term neurotoxicity has been observed and the patients benefit from excellent Quality of Life. Induction chemotherapy with two cycles of HD-MTX should be intensified to improve the unsatisfactory OAS of 30 percent.

The study of insect blood-feeding behaviour: 1. Feeding equipment, physical and endogenous factors, dose effect analysis, and diet destination

Experimental techniques that we have found useful during our studies of insect blood-feeding behaviour are reviewed. Some of the principal findings resulting from these techniques are discussed. Where directly applicable, the work of others is included, but no complete review of the subject has been attempted.

Low-Dose Vascular Photodynamic Therapy Decreases Tumor Interstitial Fluid Pressure, which Promotes Liposomal Doxorubicin Distribution in a Murine Sarcoma Metastasis Model.

INTRODUCTION: Solid tumors are known to have an abnormal vasculature that limits the distribution of chemotherapy. We have recently shown that tumor vessel modulation by low-dose photodynamic therapy (L-PDT) could improve the uptake of macromolecular chemotherapeutic agents such as liposomal doxorubicin (Liporubicin) administered subsequently. However, how this occurs is unknown. Convection, the main mechanism for drug transport between the intravascular and extravascular spaces, is mostly related to interstitial fluid pressure (IFP) and tumor blood flow (TBF). Here, we determined the changes of tumor and surrounding lung IFP and TBF before, during, and after vascular L-PDT. We also evaluated the effect of these changes on the distribution of Liporubicin administered intravenously (IV) in a lung sarcoma metastasis model. MATERIALS AND METHODS: A syngeneic methylcholanthrene-induced sarcoma cell line was implanted subpleurally in the lung of Fischer rats. Tumor/surrounding lung IFP and TBF changes induced by L-PDT were determined using the wick-in-needle technique and laser Doppler flowmetry, respectively. The spatial distribution of Liporubicin in tumor and lung tissues following IV drug administration was then assessed in L-PDT-pretreated animals and controls (no L-PDT) by epifluorescence microscopy. RESULTS: L-PDT significantly decreased tumor but not lung IFP compared to controls (no L-PDT) without affecting TBF. These conditions were associated with a significant improvement in Liporubicin distribution in tumor tissues compared to controls (P < .05). DISCUSSION: L-PDT specifically enhanced convection in blood vessels of tumor but not of normal lung tissue, which was associated with a significant improvement of Liporubicin distribution in tumors compared to controls.

Declaració sobre la crisi econòmica global i el seu impacte en les compres consorciades (19 de gener de 2009)

Redactada en nom dels molts consorcis de biblioteques de tot el món que participen a l'ICOLC, aquesta declaració té dos propòsits. Té la intenció d'ajudar als editors i altres proveïdors de contingut amb els quals tenim accés als recursos d'informació electrònica (d'ara en endavant simplement anomenats editors) a entendre millor com l'actual crisi econòmica única afecta a la comunitat de la informació de tot el món. El segon propòsit és suggerir un ventall de propostes que creiem són de benefici comú per a les biblioteques i els proveïdors de serveis d'informació.

Declaración sobre la crisis económica global y su impacto en las compras consorciadas (19 de enero de 2009)

Redactada en nombre de los muchos consorcios de bibliotecas de todo el mundo que participan en ICOLC, esta declaración tiene dos propósitos. Tiene la intención de ayudar a los editores y otros proveedores de contenido con los cuales tenemos acceso a los recursos de información electrónica (de ahora en adelante simplemente llamados editores) a entender mejor cómo la actual crisis económica única afecta a la comunidad de la información de todo el mundo. El segundo propósito es sugerir un abanico de propuestas que creemos son de beneficio común para las bibliotecas y los proveedores de servicios de información.

A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours.

BACKGROUND: EMD 521873 (Selectikine), an immunocytokine comprising a DNA-targeting antibody, aimed at tumour necrosis, fused with a genetically modified interleukin-2 (IL-2) moiety, was investigated in this first-in-human phase I study. METHODS: Patients had metastatic or locally advanced solid tumours failing previous standard therapy. Selectikine was administered as a 1-hour intravenous infusion on 3 consecutive days, every 3weeks. A subgroup of patients also received 300mg/m(2) cyclophosphamide on day 1 of each cycle. Escalating doses of Selectikine were investigated with the primary objective of determining the maximum tolerated dose (MTD). RESULTS: Thirty-nine patients were treated with Selectikine alone at dose levels from 0.075 to 0.9mg/kg, and nine were treated at doses of 0.45 and 0.6mg/kg in combination with cyclophosphamide. A dose-dependent linear increase of peak serum concentrations and area under curve was found. The dose-limiting toxicity was grade 3 skin rash at the 0.9mg/kg dose-level; the MTD was 0.6mg/kg. Rash and flu-like symptoms were the most frequent side-effects. No severe cardiovascular side-effects (hypotension or vascular leak) were observed. At all dose-levels, transient increases in total lymphocyte, eosinophil and monocyte counts were recorded. No objective tumour responses, but long periods of disease stabilisation were observed. Transient and non-neutralising Selectikine antibodies were detected in 69% of patients. CONCLUSIONS: The MTD of Selectikine with or without cyclophosphamide administered under this schedule was 0.6mg/kg. The recommended phase II dose was 0.45-0.6mg/kg. Selectikine had a favourable safety profile and induced biological effects typical for IL-2.

Estimates of radiation-absorbed dose to kidneys in patients treated with 90Y-ibritumomab tiuxetan.

The aim of the present study was to retrospectively estimate the absorbed dose to kidneys in 17 patients treated in clinical practice with 90Y-ibritumomab tiuxetan for non-Hodgkin's lymphoma, using appropriate dosimetric approaches available. METHODS: The single-view effective point source method, including background subtraction, is used for planar quantification of renal activity. Since the high uptake in the liver affects the activity estimate in the right kidney, the dose to the left kidney serves as a surrogate for the dose to both kidneys. Calculation of absorbed dose is based on the Medical Internal Radiation Dose methodology with adjustment for patient kidney mass. RESULTS: The median dose to kidneys, based on the left kidney only, is 2.1 mGy/MBq (range, 0.92-4.4), whereas a value of 2.5 mGy/MBq (range, 1.5-4.7) is obtained, considering the activity in both kidneys. CONCLUSIONS: Irrespective of the method, doses to kidneys obtained in the present study were about 10 times higher than the median dose of 0.22 mGy/MBq (range, 0.00-0.95) were originally reported from the study leading to Food and Drug Administration approval. Our results are in good agreement with kidney-dose estimates recently reported from high-dose myeloablative therapy with 90Y-ibritumomab tiuxetan.

La importancia económica de los procesos de innovación a nivel de empresa. Un análisis empírico del sector manufacturero español

Este trabajo analiza los lazos existentes entre productividad, innovación e investigación a nivel de empresa utilizando una extensión del modelo estructural de función de producción de Crépon, Duguet y Mairesse (1998). El modelo explica la productividad por medio de la innovación y, la innovación a través de la inversión en investigación. El estudio se realiza para las empresas del sector manufacturero español utilizando datos provenientes de la Encuesta sobre innovación tecnológica en las empresas 2004. Se corrigen los sesgos de selectividad y simultaneidad que se presentan dadas las características estadísticas de los datos y de las relaciones económicas entre las variables: sólo una pequeña proporción de las empresas realizan actividades de investigación; y la investigación, innovación y productividad se determinan de forma endógena. Al aplicar la forma tradicional de estimación del modelo se encuentran resultados muy similares a trabajos anteriores realizados para España. Sin embargo, se demuestra que dicha formulación no produce estimaciones consistentes, por lo que aquí se utilizan extensiones alternativas, y se exploran nuevas especificaciones para las decisiones de realizar actividades internas de investigación y desarrollo.

A control flow prototype for a dose recommending device for chronic myeloid leukemia patients

In this paper we present a prototype of a control flow for an a posteriori drug dose adaptation for Chronic Myelogenous Leukemia (CML) patients. The control flow is modeled using Timed Automata extended with Tasks (TAT) model. The feedback loop of the control flow includes the decision-making process for drug dose adaptation. This is based on the outputs of the body response model represented by the Support Vector Machine (SVM) algorithm for drug concentration prediction. The decision is further checked for conformity with the dose level rules of a medical guideline. We also have developed an automatic code synthesizer for the icycom platform as an extension of the TIMES tool.